SITE005-0287

SITE005 (FRA) › SITE005-0287

SITE005-0287

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-08-03

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-26 (study day 10); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.